Helsinki University Hospital

News

Last year, Bayer launched a project to explore the use of artificial intelligence in clinical trials, working with Finlan

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.